Changes in microvessel endothelial cell gene expression in an in vitro human breast tumour endothelial cell model

Angiogenesis

Volumn 3, Issue 3, 1999, Pages 221-229

  Hewett, Peter ^a   Popplewell, Andrew ^b   Finney, Helene ^b   Murray, J Clifford ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

Angiogenesis; Differential mRNA display; Endothelial cells; Tie 2 Tek receptor

Indexed keywords

EID: 0005202820     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009062519643     Document Type: Article

References (43)

1. Folkman J. Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-86.
2. Folkman J. What is the evidence that tumours are angiogenesis dependant. J Natl Cancer Inst 1990; 82: 4-6.
3. Fox SB, Gatter KC, Bicknell R. Relationship of endothelial cell proliferation to tumour vascularity in human breast cancer. Cancer Res 1993; 53: 4161-63.
4. Jain RK. Determinants of tumour blood supply. Cancer Res 1998; 48: 2641-58.
5. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumours and their vasculature: Implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3: 77-85.
6. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 1997; 2: 209-15.
7. Shoji M, Hancock WW, Abe K et al. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
8. Hewett PW, Murray JC. Modulation of human endothelial cell procoagulant activity in tumour endothelial models in vitro. Int J Cancer 1996; 66: 784-9.
9. Bicknell R, Harris AL. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer 1991; 27: 781-5.
10. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-96.
11. Burrows FJ, Thorpe PE. Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc Natl Acad Sci USA 1993; 90: 8996-9000.
12. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271: 603-6.
13. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med 1997; 3: 1222-7.
14. Millauer B, Longhi MP, Plate KH et al. Dominant-negative inhibition of Flk-1 suppresses then growth of many solid tumours in vivo. Cancer Res 1996; 56: 1615-20.
15. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257: 967-70.
16. Liang P, Averboukh L, Pardee AB. Distribution and cloning of eukaryotic mRNAs by means of differential display: Refinements and optimization. Nucleic Acids Res 1993; 21: 3269-75.
17. Hewett PW, Murray JC. Immunomagnetic purification of human microvessel endothelial cells using Dynabeads coated with monoclonal antibodies to PECAM-1. Eur J Cell Biol 1993; 62: 451-4.
18. Jaffe EA, Nachman RL, Becker CG, Mindi CR. Culture of human endothelial cell derived from umbilical veins: Identification by morphological and immunological criteria. J Clin Invest 1972; 52: 2745-275.
19. Hewett PW, Murray JC. Co-expression of Flt-1, Flt-4 and KDR in freshly isolated and cultured human endothelial cells. Biochem Biophys Res Commun 1996; 221: 697-702.
20. Bauer D, Muller H, Reich J et al. Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR). Nucleic Acids Res 1993; 21: 4272-80.
21. Attschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215: 403-10.
22. Mou L, Miller H, Li J, Wang E, Chalifour L. Improvements to the differential display method for gene analysis. Biochem Biophys Res Commun 1994; 199: 564-9.
23. r20,000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells. Exp Cell Res 1990; 186: 354-61.
24. Partanen J, Armstrong E, Makela TP et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 1992; 12: 1698-1707.
25. Guimaraes MJ, Lee F, Zlotnik A, McClanahan T. Differential display by PCR: Novel findings and applications. Nucleic Acids Res 1995; 23: 1832-3.
26. Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM. Ferritin protects endothelial cells from oxidized low-density lipoprotein in vitro. Am J Pathol 1995; 147: 782-9.
27. Paulson M. Basement membrane proteins: Structure, assembly and cellular interactions. Crit Rev Biochem Mol Biol 1992; 27: 93-127.
28. Sephel GC, Kennedy R, Kudrav S. Expression of capillary basement membrane components during sequential phases of wound angiogenesis. Matrix Biol 1996; 15: 263-79.
29. Paku S, Praweletz N. First steps of tumour-related angiogenesis. Lab Invest 1991; 65: 334-46.
30. Dumont DJ, Gradwohl G, Fong G-H, Auerbach R, Breitman ML. The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 1993; 8: 1293-301.
31. Schnurch H, Risau W. Expression of tie-2 a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993; 119: 957-68.
32. Ziegler SF, Bird TA, Schneringer JA, Schooley KA, Baum PR. Molecular cloning and characterization of a novel receptor protein tyrosine kinase from human placenta. Oncogene 1993; 8: 663-67001.
33. Dumont DJ, Gradwohl G, Fong G-H et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8: 1897-909.
34. Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 1996; 376: 70-74.
35. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumour angiogenesis using a soluble receptor establishes a role for tie-2 in pathologic vascular growth. J Clin Invest 1997; 100: 2072-8.
36. Lin P, Buxton JA, Acheson AS et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie-2. Proc Natl Acad Sci USA 1998; 95: 8829-34.
37. Peters K, Coogan A, Berry D et al. Expression of Tie-2/Tek in breast tumour vasculature provides anew marker for the evaluation of tumour angiogenesis. Br J Cancer 1998; 77: 51-56.
38. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997; 8: 45-62.
39. Booth BA, Boes M, Andress DL et al. IGFBP-3 and IGBP-5 association with endothelial cells: Role of C-terminal heparin binding domain. Growth Regulation 1993; 5: 1-17.
40. Linskens MHK, Feng J, Andrews WH et al. Cataloging altered gene expression in young and senescent cells using enhanced differential display. Nucleic Acids Res 1995; 23: 3244-51.
41. Grigoriev VG, Moerman EJ, Goldstein S. Senescence and cell density of human diploid fibroblasts influence metabolism of Insulin-like growth factor binding proteins. J Cell Physiol 1994; 160: 203-11.
42. Harris AL, Fox S, Bicknell R et al. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer 1994; 74: 1021-25.
43. Hewett PW, Daft EL, Murray JC. Cloning and partial characterisation of the human Tie-2 receptor tyrosine kinase promoter. Biophys Biochem Res Commun 1998; 252: 546-51.